Exploring the acceptance of a long-acting cabotegravir injectable as pre-exposure prophylaxis among university students at the University of the Western Cape.
| dc.contributor.author | Manyaka, Lethukuthula | |
| dc.date.accessioned | 2025-10-02T10:37:45Z | |
| dc.date.available | 2025-10-02T10:37:45Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | The HIV pandemic has been for many decades a global health challenge and South Africa has carried the highest burden of the disease having experienced one of the worst mortalities. Though the burden of the disease has drastically improved in the past decade, the spread of the disease continues with an annual incidence rate of about 232,400 infections in 2022, thus necessitating improved prevention measures. A highly effective method of HIV prevention is the use of Pre-exposure prophylaxis (PrEP). Often termed oral PrEP, the oral tablets containing emtricitabine and tenofovir have been available in South Africa since 2016. Since then, its use has slowly increased particularly among certain key populations, however, its overall uptake remains lower than anticipated. The newly developed long-acting cabotegravir (CAB-LA) injectable provides an opportunity to increase PrEP coverage. This is an injection containing cabotegravir, a novel antiretroviral agent against HIV. With its minimal dosing schedule of two-month intervals, a low tendency to resistance and high safety tolerance, this injectable PrEP addresses issues associated with oral PrEP usage such as poor adherence. In December 2022, the South African Health Products Regulatory Authority (SAHPRA) approved the use of CAB-LA in South Africa, consequently, the country is currently planning its rollout to the public. | |
| dc.identifier.uri | https://hdl.handle.net/10566/21009 | |
| dc.language.iso | en | |
| dc.publisher | University of the Western Cape | |
| dc.subject | Pre-exposure Prophylaxis (PrEP) | |
| dc.subject | CAB-LA | |
| dc.subject | Injectable PrEP | |
| dc.subject | Acceptance | |
| dc.subject | HIV | |
| dc.title | Exploring the acceptance of a long-acting cabotegravir injectable as pre-exposure prophylaxis among university students at the University of the Western Cape. | |
| dc.type | Thesis |